Table 2 Anthropomorphic Measurements
Variable | Treatment group | Estimated treatment effect (90Â % C.I.)a | |||
|---|---|---|---|---|---|
LLLT (N = 15) ± SD | Lorcaserin (N = 14) ± SD | Combination (N = 15b) ± SD | Combination vs. LLLT only | Combination vs. Lorcaserin only | |
Weight, kg | |||||
 Baseline | 96.0 ± 15.3 | 94.4 ± 16.2 | 90.3 ± 14.0 |  |  |
 Week 12 | 95.0 ± 14.2 | 90.7 ± 17.4 | 86.7 ± 14.2 | −2.6 (-5.0, -0.3) | +0.1 (-2.3, +2.5) |
 Delta | −1.0 ± 4.4 | −3.7 ± 3.3c | −3.5 ± 3.6c | P = .070 | P = .950 |
Weight loss of >5Â %, n (%) | 2 (13) | 8 (57) | 5 (33) | Â | Â |
Body Mass Index, kg/m2 | |||||
 Baseline | 33.5 ± 3.9 | 33.6 ± 5.1 | 33.4 ± 4.2 |  |  |
 Week 12 | 33.1 ± 3.5 | 32.3 ± 5.7 | 32.1 ± 4.3 | −1.0 (-1.8, -0.1) | +0.0 (-0.8, +0.9) |
 Delta | −0.4 ± 1.5 | −1.3 ± 1.2c | −1.3 ± 1.3c | P = .063 | P = .973 |
Waist Circumference, cm | |||||
 Baseline | 105.3 ± 11.6 | 108.0 ± 15.7 | 100.9 ± 10.0 |  |  |
 Week 12 | 103.0 ± 11.3 | 102.0 ± 16.3 | 96.9 ± 12.4 | −1.8 (-5.4, +1.7) | +1.7 (-1.9, +5.4) |
 Delta | −2.3 ± 4.1d | −6.0 ± 7.3c | −4.0 ± 5.5d | P = .398 | P = .436 |
Hip Circumference, cm | |||||
 Baseline | 119.1 ± 8.8 | 120.7 ± 12.1 | 119.0 ± 8.8 |  |  |
 Week 12 | 118.1 ± 8.3 | 116.2 ± 12.0 | 116.0 ± 9.3 | −2.0 (-3.6, -0.3) | +1.5 (-0.2, +3.2) |
 Delta | −1.0 ± 3.1 | −4.5 ± 2.1e | −3.0 ± 3.0c | P = .059 | P = .159 |
Waist-to-Hip ratio | |||||
 Baseline | 0.885 ± 0.086 | 0.892 ± 0.072 | 0.850 ± 0.063 |  |  |
 Week 12 | 0.874 ± 0.086 | 0.874 ± 0.087 | 0.834 ± 0.068 | −0.007 (-0.032, +0.018) | −0.001 (-0.027, +0.025) |
 Delta | −0.011 ± 0.035 | −0.017 ± 0.053 | −0.016 ± 0.032 | P = .657 | P = .961 |